5-fu therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer

ABSTRACT This 4 year study reports on a pharmacokinetic study for the widely used regimen of cis-platin plus continuous 5-day 5-FU as first-line chemotherapy of head and neck cancer, and the

benefit of such data for real-time therapy management. Pharmacokinetic analysis of 177 cycles for 77 patients from a group of 89 patients (group 1; 228 cycles) revealed that both the

time-concentration product (AUC) for the entire cycle and the half-cycle AUC (AUC0-3 days) were predictive of cycle toxicity. Real-time analysis of individual AUC0-3 days was used to decide

whether to reduce the dose during the second half of the cycle for a total of 249 cycles (81 patients; group 2). The dose in the second half of the course was reduced in 40% of the group 2

courses. There was a statistical difference in complete response rates between group 1 (31%) and group 2 (47%), (0.02 less than P less than 0.05) and a statistically significant reduction

was observed in the incidence of toxic cycles (greater than grade 2, group 1 = 20% versus group 2 = 12.4%; 0.02 less than P less than 0.05). Pharmacokinetic follow-up of these patients has

proved to be an objective means to improve therapeutic index significantly. Access through your institution Buy or subscribe This is a preview of subscription content, access via your

institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 24 print issues and online access $259.00 per year only $10.79 per issue Learn more Buy this

article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in

* Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS A RANDOMIZED PHASE 3 TRIAL OF GEMCITABINE OR NAB-PACLITAXEL

COMBINED WITH CISPLATIN AS FIRST-LINE TREATMENT IN PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER Article Open access 12 July 2022 INTRAVENOUS LIPOSOMAL IRINOTECAN IN METASTATIC

TRIPLE-NEGATIVE BREAST CANCER AFTER ≥ 2 PRIOR LINES OF CHEMOTHERAPY: A PHASE IB STUDY Article Open access 02 January 2025 PHASE 1 DOSE-ESCALATION STUDY EVALUATING THE SAFETY,

PHARMACOKINETICS, AND CLINICAL ACTIVITY OF OBI-3424 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS Article Open access 12 May 2023 AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Centre

Antoine Lacassagne, Nice, France J Santini Authors * J Santini View author publications You can also search for this author inPubMed Google Scholar * G Milano View author publications You

can also search for this author inPubMed Google Scholar * A Thyss View author publications You can also search for this author inPubMed Google Scholar * N Renee View author publications You

can also search for this author inPubMed Google Scholar * P Viens View author publications You can also search for this author inPubMed Google Scholar * P Ayela View author publications You

can also search for this author inPubMed Google Scholar * M Schneider View author publications You can also search for this author inPubMed Google Scholar * F Demard View author publications

You can also search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Santini, J., Milano, G., Thyss, A. _et al._

5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. _Br J Cancer_ 59, 287–290 (1989). https://doi.org/10.1038/bjc.1989.59

Download citation * Issue Date: 01 February 1989 * DOI: https://doi.org/10.1038/bjc.1989.59 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get

shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative